Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps

ClinicalTrials.gov ID: NCT05274750

Public ClinicalTrials.gov record NCT05274750. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 12:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomised, Double-blind, Parallel Group Phase III Study to Assess the Efficacy and Safety of 100 mg SC Depemokimab in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) - ANCHOR-1 (depemokimAb iN CHrOnic Rhinosinusitis)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will evaluate the efficacy and safety of depemokimab (GSK3511294) in participants with Chronic rhinosinusitis with nasal polyps (CRSwNP).

Study identification

NCT ID
NCT05274750
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
276 participants

Conditions and interventions

Conditions

Interventions

Biological · Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 22, 2022 (Actual)
Primary completion
Jul 30, 2024 (Actual)
Completion
Aug 27, 2024 (Actual)
Last update posted
Dec 3, 2025

2022 – 2024

United States locations

U.S. sites
26
U.S. states
17
U.S. cities
25
Facility City State ZIP Site status
GSK Investigational Site Tucson Arizona 85704 —
GSK Investigational Site Buena Park California 90621 —
GSK Investigational Site Los Angeles California 90006 —
GSK Investigational Site San Diego California 91942 —
GSK Investigational Site Stanford California 94304 —
GSK Investigational Site Temecula California 92592 —
GSK Investigational Site Aurora Colorado 80045 —
GSK Investigational Site Gainesville Florida 32605 —
GSK Investigational Site Tamarac Florida 33321 —
GSK Investigational Site Tampa Florida 33613 —
GSK Investigational Site Meridian Idaho 83642 —
GSK Investigational Site Meridian Idaho 83706 —
GSK Investigational Site Chicago Illinois 60612 —
GSK Investigational Site Lexington Kentucky 40509 —
GSK Investigational Site Louisville Kentucky 40205 —
GSK Investigational Site Boston Massachusetts 02135 —
GSK Investigational Site New Brunswick New Jersey 08901 —
GSK Investigational Site Great Neck New York 11021 —
GSK Investigational Site Rochester New York 14642 —
GSK Investigational Site Chapel Hill North Carolina 27599 —
GSK Investigational Site Cincinnati Ohio 45267 —
GSK Investigational Site Tulsa Oklahoma 74137 —
GSK Investigational Site Bethlehem Pennsylvania 18017 —
GSK Investigational Site Providence Rhode Island 02914 —
GSK Investigational Site Dallas Texas 75390-9035 —
GSK Investigational Site Richmond Virginia 23235 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 79 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05274750, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 3, 2025 · Synced Oct 26, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT05274750 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →